TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to announce that a patent covering the “Production of extracellular vesicles from stem cells” has been granted by IP Australia.
The patent, Australian Patent No. 2020303456, was granted on April 23, 2026 and is held by Technion Research and Development Foundation Limited. The patent relates to technology licensed exclusively to NurExone and is expected to remain in force until June 10, 2040, subject to the payment of applicable fees.